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Abstract 
 
Currently, there are two major theories for the pathogenesis of sepsis: hyperimmune 
and hypoimmune. Hyperimmune theory suggests that cytokine storm causes the 
symptoms of sepsis. On the contrary, hypoimmune theory suggests that 
immunosuppression causes the manifestations of sepsis. By using microarray study, 
this study implies that hyperactivity of TH17-like innate immunity and failure of 
adaptive immunity are noted in sepsis patients. I find out that innate immunity 
related genes are significantly up-regulated including CD14, TLR1,2,4,5,8, HSP70, 
CEBP proteins, AP1(JUNB, FOSL2), TGF-β, IL-6, TGF-α, CSF2 receptor, TNFRSF1A, 
S100A binding proteins, CCR2, formyl peptide receptor2, amyloid proteins, pentraxin, 
defensins, CLEC5A, whole complement machinery, CPD, NCF, MMP, neutrophil 
elastase, caspases, IgG and IgA Fc receptors(CD64, CD32), ALOX5, PTGS, LTB4R, LTA4H, 
and ICAM1. Majority of adaptive immunity genes are down-regulated including MHC 
related genes, TCR genes, granzymes/perforin, CD40, CD8, CD3, TCR signaling, BCR 
signaling, T & B cell specific transcription factors, NK killer receptors, and TH17 
helper specific transcription factors(STAT3, RORA, REL). In addition, Treg related 
genes are up-regulated including TGFβ, IL-15, STAT5B, SMAD2/4, CD36, and 
thrombospondin. Thus, both hyperimmune and hypoimmune play important roles in 
the pathophysiology of sepsis.  
 Introduction 
 
Despite of the discovery of antibiotics, mortality rate of sepsis is still very high. Most 
important of all, the exact pathophysiology of sepsis is still unclear. Currently, there 
are two dominant theory to explain the etiology of sepsis: hyperimmune theory and 
hypoimmune theory. However, these two theories are contrary with each other. 
Hyperimmune theory was proposed by Dr. Lewis Thomas. In his classical paper in 
NEJM 1972, he proposed that hyperactivation of proinflammatory cytokines, the 
cytokine storm, is the actual cause of sepsis symptoms. These uncontrolled cytokines 
destruct and cause multiple organ failure. His theory is the mainstream theory of 
sepsis etiology. Based on this theory, therapeutic strategy such as antibody 
neutralizing TNFα was tested in septic patients in clinical trials. However, these 
antibodies did not improve the survival rate of septic patients. Further, anti-TNFα 
increased the mortality rate of septic patients in several clinical trials. That makes 
people to doubt the hyperimmune theory. Thus, another theory-hypoimmune theory 
emerges. Based on the observation that immunosuppressive patients are prone to 
get sepsis, hypoimmune status was suggested to be the etiology of sepsis. However, 
the hypoimmune theory cannot successfully explain the proinflmmatory cytokines 
storm noted in sepsis. Both hyperimmune theory and hypoimmune theory have 
clinical and experimental evidences. However, they are contrary with each other. 
Here, I use the microarray study of whole blood of septic patients to propose a new 
theory: Sepsis is a syndrome of hyperactivity of innate immunity and hypoactivity of 
adaptive immunity. This new theory solves the above controversy.  
 
Material and Methods 
 
Microarray dataset 
 
According to Dr. J. A. Howrylak’s research in Physiol Genomics 2009, he collected 
total RNA from whole blood in sepsis and sepsis induced ARDS patients.(1) He tried 
to find out molecular signature of ARDS compared to sepsis patients. His dataset is 
available in Gene Expression Omnibus (GEO) www.ncbi.nlm.nih.gov/geo (assession 
number GSE 10474). I use his samples of sepsis patients from this dataset to do the 
further microarray analysis. The sample size is 21 patients with 35% mortality rate. 
The second dataset is from GSE20189 of Gene Expression Omnibus. This dataset was 
collected by Dr. Melissa Rotunno in Cancer Prevention Research 2011.(2) Molecular 
signature of early stage of lung adenocarcinoma was studied by microarray. I use the 
healthy control (sample size 21)whole blood RNA from this dataset to compare the 
septic patients. In this study, I perform further analysis to study peripheral leukocyte 
gene expression profiles of sepsis compared to those of healthy controls.  
 
Statistical analysis 
 
Affymetrix HG-U133A 2.0 genechip was used in both samples. RMA express 
software(UC Berkeley, Board Institute) is used to do normalization and to rule out the 
outliners of the above dataset. I rule out the potential outliners of samples due to 
the following criteria:  
1. Remove samples which have strong deviation in NUSE plot 
2. Remove samples which have broad spectrum in RLE value plot 
3. Remove samples which have strong deviation in RLE-NUSE mutiplot 
4. Remove samples which exceed 99% line in RLE-NUSE T2 plot 
 
Then, Genespring XI software was done to analysis the significant expressed genes 
between ARDS and healthy control leukocytes. P value cut-off point is less than 0.05. 
Fold changecut-off point is >2.0 fold change. Benjamini-hochberg corrected false 
discovery rate was used during the analysis. Totally, a genelist of 3277 genes was 
generated from the HGU133A2.0 chip with 18400 transcripts including 14500 
well-characterized human genes. 
 
RT-PCR confirmation 
 
Dr. J. A. Howrylak performed real time PCR for selected transcripts (cip1, kip2) by 
using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA).  In the 
second dataset, Dr. Melissa Rotunno also performed qRT-PCR test to validate the 
microarray results. RNA quantity and quality was determined by using RNA 600 
LabChip-Aligent 2100 Bioanalyzer. RNA purification was done by the reagents from 
Qiagen Inc. All real-time PCRs were conducted by using an ABI Prism 7000 Sequence 
Detection System with the designed primers and probes for target genes and an 
internal control gene-GAPDH. This confirms that their microarray results are 
convincing compared to RT-PCR results. 
 
Results 
 
RMA analysis of whole blood from healthy normal control 
 
The RMA analysis was performed for RNA samples from whole blood of healthy 
control of the lung adenocarcinoma dataset. Raw boxplot, NUSE plot, RLE value plot, 
RLE-NUSE multiplot, and RLE-NUSE T2 plot were generated. Then, sample was 
included and excluded by using these graphs(Figure 1A, 1B, 1C, 1D, 1E). Because of 
the strong deviation in the T2 plot, the sample GSM506435 was removed for the 
further analysis.  
 
RMA analysis of whole blood from septic patients 
 
The RMA analysis was performed for RNA samples from whole blood of sepsis 
patients dataset. Raw boxplot, NUSE plot, RLE value plot, RLE-NUSE multiplot, and 
RLE-NUSE T2 plot were generated. Then, sample was included and excluded by using 
these graphs(Figure 2A, 2B, 2C, 2D, 2E). GSM265024 and GSM265030 are removed 
due to above criteria. 
 
Toll-like signaling and heat shock protein expression in septic patients 
According to the microarray analysis, Toll-like receptors 1, 2, 4, 5, 8 are up-regulated 
in sepsis.(Table 1) CD14 molecule and downstream signaling such as IRAK4 and TAB2 
are also up-regulated. TLR1, 2, 4, 5, 8 are mediating anti-bacterial immune response. 
Thus, TH17-like proinflamatory cytokines such as IL-6 will be triggered. However, the 
negative TLR regulator-IRAK3 is 21 fold up-regulated. Thus, TLR 1, 2, 4, 5, 8 signaling 
may not successfully trigger proinflammatory cytokines. Other pathway such as CD14 
may act as an important alternative pathway to trigger IL-6 and other TH17-like 
cytokines. Other pattern recognition receptors such as formyl peptide receptors 
(FPR)which can recognize specific bacterial antigen to trigger innate immunity are 
also differentially expressed. FPR1 is 7.6 fold down-regulated, but FPR2 is 4.7 fold 
up-regulated.  
In table 2, we can see that many heat shock protein genes are up-regulated. Fever is 
a usual manifestation of sepsis. Thus, it is not surprising that heat shock proteins are 
expressed during sepsis. Among them, heat shock protein 70 (HSPA1A/1B) is 7 fold 
up-regulated. HSP70 can bind to TLR4 to trigger anti-bacterial TH17-like innate 
immunity. It is worth noting that HSP90AA1 is 13 fold down-regulated. HSP90 can 
bind to steroid receptor and prevent its action. If HSP90 is down-regulated, the 
action of steroid cannot be stopped. Thus, steroid related immune regulatory effect 
may be initiated during sepsis. 
 
Antigen processing and antigen presentation genes in sepsis 
In table 3 and table 4, we can see many cathepsin and proteasome genes are 
up-regulated. Up-regulated cathepsin genes include CTSA, CTSD, CTSC, CTSG, and 
CTSZ. But, CTSO and CTSW are down-regulated. Cathepsin W (CTSW) is related to 
CD8 T cell activation.(3) Up-regulated proteasome genes include PSMD13, PSMC6, 
PSMD12, PSMD5, PSMB6, and PSMD10. Down-regulated proteasome genes include 
PSMF1, PSMC2, and PSME4, Among them, PSMF1 is a proteasome inhibitor. Both 
cathepsins and proteasomes are important in the antigen processing pathways. We 
can see antigen processing after bacterial infection is intact.  
 
In table 5, however, we can see all MHC related genes are down-regulated in 
leukocytes of septic patients. These down-regulated genes include HLA-DPB, 
HLA-DQA, HLA-DRB, HLA-DOB, HLA-DRA, HLA-DQB, Tapasin, MHC I related transcripts, 
HLA-B, and HLA-DPA. Among them, HLA-B is more than 11 fold down-regulated. MHC 
genes are keys to the antigen presentation to trigger adaptive immune reaction such 
as B cell or T cell activation. Since all the MHC related genes are down-regulated, 
antigen presentation during sepsis is likely to be impaired. This matches previous 
observations.(4)  
 
TH17-like innate immune transcription factors in sepsis 
 
In table 6, many immune related transcription factors are differentially regulated 
during sepsis. First of all, many innate immunity related transcription factors are 
up-regulated in septic patients. These include AP1(JunB and FosL2), NFIL3, ARNT, and 
CEBP(CEBPA, CEBPG, and CEBPD) genes. Aryl hydrocarbon receptor nuclear 
translocator(ARNT) plays an important role in the activation of TH17-like innate 
immunity. CEBP family genes are related to the activity of myeloid cells and 
granulocytes. CEBP genes are also related to the activation of acute response 
proteins. In addition, the inhibitor of NFkB, NFKBIA, is down-regulated in sepsis. It 
means that the activity of NFkB, an key innate immunity mediator, is up-regulated in 
septic patients. It is worth noting that two important transcription factors: High 
Mobility Group Box(HMGB) and Hypoxia inducible factor alpha(HIFα) are also 
up-regulated during sepsis. HMGB, a vital innate immunity mediator, is greater than 
nine fold up-regulation. 
 
STAT1, a key transcription factor for TH1 and THαβ immunity, is down-regulated in 
sepsis. In addition, TBX21(T-bet), a key TH1 immune response driver, is also 
down-regulated. (Table 25) In addition, MafB which can suppress IFNαβ in THαβ 
immunity is up-regulated(5). Other TH2 related key transcription factors such as 
GATA3 and C-MAF are also down-regulated.(6) It means that TH1, TH2, and THαβ are 
down-regulated in sepsis. Surprisingly, key TH17 related transcription factors are also 
down-regulated including REL, STAT3, and RORA.(7) Besides, SOCS3, a negative 
regulator of the central TH17 transcription factor STAT3, is up-regulated. It means 
that TH17 helper cells cannot be successfully triggered. On the other hand, Treg and 
TGFβ signaling are up-regulated including STAT5B, IL-15, SMAD2, and SMAD4.(8, 9) 
TH17 and Treg associated aryl hydrocarbon receptor nuclear translocator(ARNT) is 
also up-regulated in sepsis.(10) Thus, Treg cells are likely to be activated in sepsis. 
This matches the previous observations that Treg cells are up-regulated during sepsis.  
 
TH17-like and Treg related cytokines are up-regulated during sepsis 
 
In table 7, many TH17-like and Treg related cytokines are up-regulated in septic 
patients. The whole TGFβ activation machinery is up-regulated including 
thrombospondin, CD36, and TGFβ itself. TGFA and IL-15 are also up-regulated. 
Besides, IL-6 is also up-regulated in sepsis. Thus, both key TH17 driven cytokines, 
TGFβ and IL-6, are activated in septic patients. However, full activation of TH17 
helper cells also need a TCR signaling. IL-32, a TH1 related macrophage 
differentiation factor, is down-regulated.(11) TH22 mediators, IL1A is down-regulated 
and IL1RN (IL1 receptor antagonist is up-regulated. It means that TH22 is not 
activated in sepsis.  
 In table 8, cytokine receptors are differentially regulated in sepsis. On the contrary 
with cytokine, cytokine in a certain immunological pathway is usually 
down-regulated. Thus, since TH17-like immunity is activated. TGFBR3, IL6R, and 
IL17RA are all down-regulated. TGFβ receptor 3 is greater than 11 fold 
down-regulated, and interleukin 6 receptor is greater than 16 fold down-regulated. 
Treg is also triggered in sepsis, so TGFBR3, IL2RB, and IL7R are also down-regulated. 
TH1 related cytokine receptors, IFNGR1 and IFNGR2, are up-regulated. TH2 cytokine 
receptor, IL4R, is also up-regulated. As for THαβ immunity, IFNAR1 is up-regulated 
but IFNAR2 is down-regulated. TH22 cytokine receptors, IL1R1 and IL1R2, are 
up-regulated. Thus, TH1, TH2, THαβ, and TH22 are not activated during sepsis.  
 
In table 9, important CSF receptors are up-regulated. These include CSF2 (GM-CSF) 
receptor α and β. GM-CSF can promote the proliferation of monocyte and 
granulocyte lineages. In table 10, many TNF related genes are differentially regulated. 
Up-regulated TNF related genes include TNFAIP6, TNFAIP8, TNFRSF1A and TNFSF10. 
Down-regulated TNF related genes include TNFRSF10C, TNFRSF9, and TNFSF14. 
TNFRSF1A is the major receptor of TNFα. Thus, both IL-1 receptor and TNFα receptor 
are up-regulated during sepsis. TNFSF10(TRAIL) is a pro-apoptotic factor, and 
TNFRSF10C is a receptor to prevent TRAIL induced apoptosis. Thus, TRAIL induced 
apoptosis pathway is activated in sepsis. TNFRSF9(4-1BB) and TNFSF14(CD258) are 
both important lymphocyte co-stimulatory molecules. Thus, lymphocyte 
costimulation is likely to be impaired at sepsis.   
 
TH17 related chemokine up-regulation during sepsis 
 
In table 11, we find out that TH17 related chemokine are up-regulated in septic 
patients. These chemokines include S100 binding proteins (S100A11, S100A8, 
S100A9, and S100P), CCR2(neutrophil chemokine receptor), hyaluronan-mediated 
motility receptor (HMMR), and chemokine-like factor(CKLF). THαβ related chemokine 
factors such as CX3CR1, XCL1, and XCL2 for NK cell recruitment are down-regulated. 
TH1 related chemokine factors such as CCL4 and CCR1 for macrophage/monocyte 
recruitment are also down-regulated. Besides, TH2 chemokine receptor CCR3 for 
eosinophil recruitment is also down-regulated. It is worth noting that CCR7, the 
chemokine receptor for central memory T cells, is greater than 5 fold down-regulated 
in sepsis. Thus, the generation of central memory T cell is likely to be impaired during 
sepsis.  
In table 12, many prostaglandin and leukotriene genes are differentially regulated. 
Prostaglandins and leukotrienes are important chemotaxis mediators. The key 
enzyme: leukotriene A4 hydrolase for synthesizing leukotriene B4, a potent PMN 
chemoattractant, is up-regulated. Besides, leukotriene B4 receptor is also 
up-regulated. Besides, the receptor of PGD2, a TH2 related effector molecule, is 10 
fold down-regulated. Prostangin D synthetase is also down-regulated. In addition, the 
gene 15-hydroxyprostaglandin dehydrogenase (HPGD), which is responsible for 
shutting down prostaglandin, is 16 fold up-regulated. Key molecules including 
phospholipase A 2 and arachidonate 5-lipoxygenase to initiate leukotriene synthesis 
are also up-regulated in sepsis. 
 
Th17-like innate immunity related effector molecule up-regulation in sepsis 
 
In table 13, many acute response proteins are up-regulated. These acute phase 
proteins are up-regulated by IL-6 and CEBP proteins. These genes include amyloid 
proteins (APP and APLP2), pentraxin(PTX3), transferrin receptor(TFRC), CLEC (CLEC5A 
and CLEC1B), and defensins (DEFA1, DEFA1B, DEFA3, and DEFA4). These above 
proteins are innate immunity effector proteins to attack bacterial antigens 
non-specifically. Defensin A4 is greater than 6 fold up-regulated. 
In table 14, the whole set complement machinery, an important effector component 
of innate immunity, is up-regulated. These include CD59, CD55, C1QB, ITGAM, CR1, 
CD46, C3AR1, ITGAX, C1QA, C1RL, C5AR1, and CD97. Thus, complement molecules 
are activated during sepsis. These complement molecules attack bacterial cell walls 
and membranes to cause their damage. However, complements may also cause 
harmful effect to the host. 
In table 15, certain genes related to PMN phagocytosis and bacteria killing are 
up-regulated. Neutrophil cytosolic factor 1&4, the subunit of NADPH oxidase for 
ingested bacteria killing, are up-regulated in sepsis. Carboxypeptidase D (CPD), which 
can up-regulate nitric oxide, is also up-regulated during sepsis.(12) Nitric oxide is also 
a key effector molecule for ingested bacteria killing. CPD is greater than 6.9 fold 
up-regulated.  
In table 16, PMN matrix metallopeptidases(MMP) and elastase are up-regulated. 
These protein enzymes can digest bacterial antigens as well as extracellular matrix. 
These genes include MMP8, MMP9, MMP25, and ELANE(elastase). In addition, tissue 
inhibitor of MMP, TIMP2, and serum inhibitors of elastase or proteinase, SERPINA1, 
SERPINB1, and SERPINB2, are also up-regulated. It means that PMN proteinases are 
dysregulated. It is worth noting that MMP8 is 32 fold up-regulated and MMP9 is 10 
fold up-regulated.  
In table 17, apoptosis machinery is up-regulated during sepsis. Up-regulated genes 
include casapase3, FAS, caspase5, program cell death 10(PDCD10), caspase 1, 
caspase4, and TRAIL. Down-regulated genes include CFLAR and FAIM3, both of which 
are apoptosis negative regulators. Thus, apoptosis is activated at sepsis. It matches 
previous observations that there is massive leukocyte-lymphocyte apoptosis during 
sepsis.  
In table 18, many Fc receptor genes which mediate macrophage and neutrophil 
phagocytosis are up-regulated. These genes include IgG Fc receptor IIa(FCGR2A), IgE 
Fc receptor Ig(FCER1G), IgA Fc receptor(FCAR), IgG Fc receptor IIc(FCGR2C), IgG Fc 
receptor Ib, and IgG Fc receptor Ia/Ic(FCGR1A/1C). Besides, TH2 immunity related IgE 
Fc receptor Ia is 3.8 fold down-regulated. In addition, THαβ immunity related CD16 
IgG Fc receptor expression is unchanged. TH17-related innate immunity is mediated 
by IgG(IgG2/IgG3) and IgA. Thus, TH17-like innate immunity with enhanced 
phagocytosis is noted during sepsis. 
In table 19, many CD molecules are up-regulated or down-regulated during sepsis. 
These CD molecules are important immune response mediators. Among them, 
up-regulation of CD36, the thrombospodin receptor, means that TGFβ molecule is 
also up-regulated. Down-regulated CD2 molecule means that T cell activation 
pathway is impaired. In addition, down-regulation of CD40 means that activation of 
antigen presenting cells such as B cells is impaired. Besides, CD24 is usually 
down-regulated in memory B cells. However, during sepsis, CD24 is strongly 
up-regulated.  
 
Coagulation , glycolysis, acidosis, and vasodilation gene dysregulation in sepsis 
In table20, many coagulation related genes are dysregulated during sepsis. Actually, 
disseminated intracellular coagulopathy is a common manifestation of sepsis. 
Up-regulated coagulation genes include F13A1, F5, F8, GP1BB, PROS1, PLAUR, 
MCFD2, TFPI, F2RL1, ITGA2B, PDGFC, ITGB3, and THBD. Both coagulation factors and 
inhibitors are dysregulated in sepsis.  
 
The whole glycolytic pathway enzymes are up-regulated during sepsis.(Table21) 
These include lactate dehydrogenase A, phosphoglycerate kinase 1, pyruvate kinase, 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, hexokinase 2, glycogen 
phosphorylase, 2,3-bisphosphoglycerate mutase, hexokinase 3, glucose-6-phosphate 
isomerase, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2, 
glyceraldehyde-3-phosphate dehydrogenase, enolase 1, and phosphoglycerate 
kinase 1. In addition, the enzyme, pyruvate dehydrogenase kinase, which can stop 
pyruvate to form acetyl-CoA is up-regulated. The enzyme, pyruvate dehyrogenase 
phosphatase, which can facilitate pyruvate to form acetyl-CoA to enter aerobic citric 
acid cycle is down-regulated in sepsis. Thus, pyruvate can keep on forming lactate in 
anaerobic pathway during sepsis.  
 
Concurrently, H+-ATPases are also up-regulated during sepsis(Table22). In my 
previous article(paper in press), I find out the coupling between glycolytic enzymes 
and H+-ATPases during falciparum malarial infection. Here, I also find out 
up-regulated H+-ATPases including ATP6V0B, ATP6V0E1, ATP6AP2, ATP6V1C1, 
TCIRG1, ATP6V1D, ATP11B, and ATP11A. Besides, carbonic anhydrase IV & II, which 
can produce H2CO3, are up-regulated in sepsis. Thus, this can help to explain the 
acidosis during sepsis.  
 
Hypotension is a complication of sepsis. Septic shock is related to global vasodilation. 
In table 23, several key vasodilation genes are up-regulated. These genes including 
angiotensinase c (PRCP), adrenomedullin(ADM), and monoamine oxidase A(MAO-A). 
Angiotensin is a very strong vasopressor, and angiotensinase can metabolize 
angiotensin to inhibit its function. Adrenomedullin is a potent vasodilator. MAO-A 
can metabolize three key endogenous vasoconstrictors: dopamine, epinephrine, and 
norepinephrine. Thus, elevated MAO-A can prevent the effect of hypertensive 
agents. Thus, the findings can help to explain the etiology of septic shock.  
 Failure of NK, B, T lymphocyte adaptive immunity during sepsis 
Lymphocytes play important roles in adaptive immunity. In sepsis, the three major 
lymphocyte populations: NK cells, T cells, and B cells are all down-regulated. Thus, 
lymphocyte adaptive immunity fails to induce during sepsis. This is very important is 
sepsis pathogenesis.  
In table 24, majority of NK cell related genes are down-regulated including NK cell 
killer receptors (NKTR, KLRK1, LAIR2, KLRD1, KLRG1, KLRB1, and KLRF1), granzymes 
(GZMA, GZMK, GZMB, and GZMH), and perforin (PRF1). Thus, NK lymphocytes are 
inactivated or even suppressed during sepsis. NK cells are very important in THαβ 
immunity, and it also implies that THαβ immunity is inhibited during sepsis.  
In table 25, many T cell related genes are also down-regulated. These 
down-regulated genes include TCR genes(TRAC, TARP, TRBC1/C2, TRD@, TRGC2, and 
TRDV3), CD costimulatory molecules(CD3E, CD8A, CD3G, LY9, CD3D,CD2), T cell 
specific transcription factors(IKZF1, TCF7, NFAT5, NFATC3, TCF7L2, NFATC2IP, TBX21, 
ID2, and ID2B), granzyme/perforin (GZMA, GNLY, GZMK, GZMB, GZMH, and PRF1), 
and TCR downstream signaling(ZAP70 and LCK)(13). Thus, the whole-set of T cell 
activation machinery is suppressed. Both CD4 helper T cells and CD8 cytotoxic T cells 
are inactivated and down-regulated in septic patients.  
In table 25, B cell genes are differentially regulated. Up-regulated B cell related 
genes include immunoglobulin light chain(IGK, IGJ, and IGKV1-5), immunoglobulin 
heavy chain(IGHG1/G2 and IGHA1/A2), and B cell suppressive transcription 
factors(BCL6 and IBTK)(14). Down-regulated genes include B cell stimulatory 
transcription factor (PAX5 and IKZF1), immunoglobulin heavy chain(IGHM), BCR 
signaling(FYN and LYN), and PI3K signaling(PIK3CB, PIK3IP1, PIK3CG, and 
PIK3R1)(15-17). The negative regulator of PI3K signaling, PTEN, is 4.6 fold 
up-regulated. BCL6 and IBTK can inhibit B cell differentiation and activation. PI3K 
signaling is the downstream stimulatory pathway of B cell activation. Thus, BCR 
signaling appears to be suppressed during sepsis. Although Ig light chain and 
IgA/IgG2 are up-regulated, this may be due to the isotype switch effect of 
up-regulated immunosuppressant TGF-β. The key immunoglobulin, IgM, for bacteria 
defense is down-regulated. It implies that B cell adaptive immunity is also impaired 
at sepsis.  
 
Discussion 
Despite of current antibiotics treatment, sepsis still causes a very high mortality. The 
pathophysiology of sepsis is still unclear.(18, 19) The most dominant theory for sepsis 
mechanism is hyperimmune.(20) Hyperimmunity with cytokine storm was observed 
in sepsis by Dr. Lewis Thomas.(21) He suggested the symptom and sign in sepsis is 
due to the overactivity of pro-inflammatory cytokines in a NEJM paper. His theory is 
widely accepted. Based on his hyperimmune theory, many therapeutic strategies 
were developed. Most famous approach is the anti-TNF agent in sepsis clinical trials. 
Because the pro-inflammatory cytokine TNFα is up-regulated in sepsis, use of 
anti-TNF agent should help to control sepsis. However, the result is opposite. Usage 
of anti-TNF agent increase the sepsis mortality rate.(22-24) Thus, the 
sepsis-hyperimmune theory is doubtful.  
The other sepsis pathophysiology theory emerged. This is the hypoimmune theory. 
Because immunocompromised patients are prone to develop sepsis, hypoimmune 
should be related to the cause of sepsis.(25) In addition, massive effector lymphocyte 
apoptosis, depletion of dendritic cells, and elevated Treg cells are noted during 
sepsis.(26-30) In previous reports, down-regulation of co-stimulatory molecules and 
MHC are noted in septic patients.(31) In addition, B cells play important roles in 
recovery from sepsis status.(32) This hypothesis is not accepted by most scientists 
because it cannot explain the observed cytokine storm during sepsis. Thus, both 
theories have some evidence support and both are only partially correct.  
 
Thus, the third theory proposed. This is the sequence theory. There is hyperimmune 
first during sepsis, and then hypoimmune follows. This theory tried to incoperate 
both theories. However, it is not clear why there will be such sequential immune 
response. There is no existing immunological mechanism to explain this sequential 
effect. Why does the hyperimmune happen first? Why does the hyperimmune 
become to be hypoimmune? In addition, immunodeficiency patients are easily get 
sepsis. Then, why do these immunodeficiency patients easily develop hyperimmune 
status first? Current sepsis theory cannot well explain this.  
 
In this study, I use microarray analysis to demonstrate that sepsis is actually a 
hyperactivity of innate immunity and hypoactivity of adaptive immunity. Thus, it can 
well explain the co-existence of hyperimmune and hypoimmune. The hypoimmune 
adaptive immunity explains why immunocompromised patients tend to suffer from 
sepsis easily. The hyperimmune innate immunity explains why pro-inflammatory 
cytokine storm is observed at sepsis. The adaptive immune dysfunction with lack of T 
helper cells is the key to sepsis pathogenesis. Thus, block TH17 related cytokines 
such as TNFα can further stop the successful generation of TH17 helper cells to 
initiate adaptive immunity to combat extracellular bacteria. Thus, it can explain why 
TNF blockade increase the mortality rate of sepsis patients.  
 
In the microarray study, I find out evidences to support my theory. The whole blood 
from septic patients can reflect the leukocyte expression patterns. I find out that 
innate immunity related genes are significantly up-regulated. These genes include 
CD14, TLR1,2,4,5,8, HSP70, CEBP proteins, AP1(JUNB, FOSL2), TGF-β, IL-6, TGF-α, 
CSF2 receptor, TNFRSF1A, S100A binding proteins, CCR2, formyl peptide receptor2, 
amyloid proteins, pentraxin, defensins, CLEC5A, whole complement machinery, CPD, 
NCF, MMP, neutrophil elastase, caspases, IgG and IgA Fc receptors(CD64, CD32), 
ALOX5, PTGS, LTB4R, LTA4H, and ICAM1. I also find out that majority of adaptive 
immunity genes are down-regulated including MHC related genes, TCR genes, 
granzymes/perforin, CD40, CD8, CD3, TCR signaling, BCR signaling, T & B cell specific 
transcription factors, NK killer receptors, and TH17 helper specific transcription 
factors(STAT3, RORA, REL). In addition, Treg related genes are up-regulated including 
TGFβ, IL-15, STAT5B, SMAD2/4, CD36, and thrombospondin. Up-regulated regulatory 
cells during sepsis are also shown in other previous studies. Up-regulated Treg 
related genes can also suppress the adaptive immunity in sepsis. These all support 
my sepsis pathogenesis.  
 
Sepsis is also related to several complications such as disseminated intravascular 
coagulation(DIC), hypotension/shock, and lactate acidosis.(33) In this microarray 
analysis, I find out that many coagulation related genes are up-regulated during 
sepsis including factor5, factor8, facto13, protein S, plasminogen receptor, ITGA2B, 
ITGB3, and thrombomodulin. Thus, it can help to explain the mechanism of DIC 
during sepsis. Several hypotensive agents are also up-regulated in sepsis including 
angiotesinase C, adrenomodullin, and MAO-A. This can help to explain septic shock 
pathophysiology. The whole set of glycolytic enzymes are up-regulated during sepsis 
including LDHA, PGK1, PKM2, PFKFB3, HK2, PYGL, BPGM, HK3, PDK3, GPI, PFKFB2, 
GAPDH, and ENO1. In addition, glycolytic enzyme coupled H+-ATPase genes are also 
up-regulated. These can explain the lactate acidosis noted during sepsis.  
 
Bacteria have strategies to suppress host immunity for their survival, especially the 
adaptive immunity.(34) In conclusion, after knowing the pathogenesis of sepsis, we 
can develop better preventive and therapeutic agents to control sepsis. The 
impairment of adaptive immunity could be more important than the overactivation 
of innate immunity during sepsis. Thus, we may use medications to activate host 
adaptive immunity such as T helper cells to combat sepsis. In addition, we can also 
develop therapeutic strategies to cope with sepsis related complications such as DIC, 
hypotension, and lactate acidosis. Hopefully, the detrimental illness-sepsis will be 
overcome one day. 
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Figure legends 
 
Figure 1. RMA express plot for selecting samples in normal healthy controls. 
1-A NUSE boxplot for normal control 
1-B RLE boxplot for normal control 
1-C RLE-NUSE multiplot for normal control 
1-D RLE-NUSE T2 plot for normal control 
1-E Raw data Boxpolt for normal control 
 
Figure 2. RMA express plot for selecting samples in septic patients. 
2-A NUSE boxplot for septic patients 
2-B RLE boxplot for septic patients 
2-C RLE-NUSE multiplot for septic patients 
2-D RLE-NUSE T2 plot for septic patients 
2-E Raw data Boxplot for septic patients 
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Table 1. TLR 
   Probe ID Pvalue Arrow Fold Gene 
201743_at 1.37E-04 up 2.176301 CD14 
204924_at 1.45E-10 up 3.380896 TLR2 
210166_at 9.16E-08 up 2.395743 TLR5 
210176_at 0.001131 up 2.073326 TLR1 
213817_at 3.14E-13 up 21.0364 IRAK3 
219618_at 1.89E-09 up 2.692996 IRAK4 
220832_at 4.76E-09 up 5.164016 TLR8 
221060_s_at 6.62E-07 up 3.331681 TLR4 
212184_s_at 2.03E-05 up 2.61743 TAB2 
221705_s_at 8.46E-10 down 2.07506 SIKE1 
205118_at 1.05E-10 down 7.612908 FPR1 
210772_at 2.06E-08 up 4.776773 FPR2 
210773_s_at 2.95E-06 up 4.516464 FPR2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. HSP 
    Probe ID Pvalue Arrow Fold Gene 
200598_s_at 4.02E-04 down 2.112279 HSP90B1 
200599_s_at 6.27E-04 up 2.143909 HSP90B1 
200800_s_at 8.98E-09 up 2.664816 HSPA1A /1B 
200941_at 1.29E-10 up 2.175182 HSBP1 
200942_s_at 7.06E-08 up 2.197023 HSBP1 
202557_at 1.10E-05 up 2.82175 HSPA13 
202558_s_at 7.12E-05 up 2.112017 HSPA13 
202581_at 1.98E-14 up 7.20045 HSPA1A/1B 
202842_s_at 6.81E-06 up 2.73954 DNAJB9 
202843_at 8.03E-07 up 2.087716 DNAJB9 
206782_s_at 1.21E-09 up 2.374709 DNAJC4 
208810_at 3.57E-04 up 2.196654 DNAJB6  
209015_s_at 9.66E-09 up 2.548422 DNAJB6 
209157_at 1.97E-10 up 2.893105 DNAJA2 
210338_s_at 1.85E-05 down 2.06926 HSPA8 
211936_at 1.05E-07 up 2.110743 HSPA5 
211969_at 3.39E-17 down 13.51482 HSP90AA1 
212467_at 1.01E-07 up 3.702917 DNAJC13 
212911_at 1.88E-13 up 3.009307 DNAJC16 
219237_s_at 2.18E-04 down 2.275608 DNAJB14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Cathepsin 
   Probe ID Pvalue Arrow Fold Gene 
200661_at 6.28E-10 up 2.550876 CTSA 
200766_at 3.53E-12 up 3.746886 CTSD 
201487_at 7.15E-06 up 2.584763 CTSC 
203758_at 4.23E-08 down 2.3372 CTSO 
205653_at 1.36E-04 up 3.234722 CTSG 
210042_s_at 2.94E-07 up 3.044302 CTSZ 
214450_at 2.16E-06 down 2.202781 CTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Proteasome 
   Probe ID Pvalue Arrow Fold Gene 
201052_s_at 8.16E-06 down 2.218188 PSMF1 
201067_at 3.68E-20 down 4.692738 PSMC2 
201232_s_at 5.58E-11 up 2.577756 PSMD13 
201699_at 2.88E-08 up 4.61153 PSMC6 
202352_s_at 1.45E-08 up 2.49783 PSMD12 
202353_s_at 1.04E-07 up 2.4536 PSMD12 
202753_at 6.55E-08 up 2.001992 PSMD6 
203447_at 1.23E-10 up 2.450336 PSMD5 
208805_at 6.04E-05 up 2.094127 PSMA6 
208827_at 4.41E-09 up 2.513269 PSMB6 
212220_at 1.31E-09 down 3.309962 PSME4 
219485_s_at 1.85E-07 up 2.271658 PSMD10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. MHC 
   Probe ID Pvalue Arrow Fold Gene 
201137_s_at 5.80E-04 down 2.085101 HLA-DPB1 
203290_at 2.56E-08 down 5.193201 HLA-DQA1 
204670_x_at 6.77E-08 down 2.848446 HLA-DRB1/B4 
205671_s_at 1.27E-04 down 2.016965 HLA-DOB 
208306_x_at 1.53E-06 down 2.437791 HLA-DRB1 
208894_at 8.06E-07 down 2.762713 HLA-DRA 
209312_x_at 1.24E-06 down 2.674953 HLA-DRB1/B4/B5 
209823_x_at 8.65E-04 down 2.083243 HLA-DQB1 
210294_at 7.08E-10 down 2.247553 TAPBP 
210528_at 1.28E-05 down 2.565486 MR1 
210982_s_at 4.46E-05 down 2.140575 HLA-DRA 
211944_at 5.60E-22 down 7.377162 BAT2L2 
211947_s_at 9.14E-14 down 4.692785 BAT2L2 
211948_x_at 3.66E-28 down 11.74736 BAT2L2 
211990_at 5.10E-06 down 3.188215 HLA-DPA1 
211991_s_at 1.47E-05 down 2.428313 HLA-DPA1 
212384_at 8.83E-15 down 2.983359 HLABAT1 
212671_s_at 0.002545 down 2.265915 HLA-DQA1/A2 
213537_at 7.83E-05 down 2.338689 HLA-DPA1 
214052_x_at 4.45E-14 down 2.404988 BAT2L2 
214055_x_at 1.16E-24 down 9.415468 BAT2L2 
215193_x_at 2.90E-06 down 2.522364 HLA-DRB1/B3/B4 
221491_x_at 1.50E-06 down 2.247077 HLA-DRB1/B3/B4/B5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Transcription factor 
   Probe ID Pvalue Arrow Fold Gene 
M97935_MA_at 1.92E-04 down 2.010955 STAT1 
201473_at 3.65E-09 up 2.459731 JUNB 
201502_s_at 9.16E-07 down 2.364327 NFKBIA 
202527_s_at 5.77E-09 up 3.237444 SMAD4 
203075_at 3.46E-06 up 2.133481 SMAD2 
203077_s_at 4.90E-07 up 2.370214 SMAD2 
203574_at 4.37E-10 up 5.176725 NFIL3 
204039_at 4.62E-08 up 2.059098 CEBPA 
204203_at 9.92E-07 up 2.172468 CEBPG 
205026_at 1.66E-09 up 2.20184 STAT5B 
205841_at 1.02E-13 up 4.655113 JAK2 
205842_s_at 6.01E-07 up 2.878639 JAK2 
206035_at 7.43E-10 down 2.106359 REL 
206036_s_at 8.46E-12 down 4.746634 REL 
206359_at 3.22E-07 up 2.092249 SOCS3 
206363_at 9.68E-06 down 2.261549 MAF 
208991_at 1.49E-13 down 3.223685 STAT3 
209604_s_at 2.74E-19 down 6.546836 GATA3 
209969_s_at 2.12E-08 down 4.748202 STAT1 
210426_x_at 1.14E-12 down 6.358444 RORA 
210479_s_at 5.21E-15 down 7.850211 RORA 
212501_at 1.73E-07 up 2.169912 CEBPB 
212549_at 7.00E-12 up 2.369991 STAT5B 
212550_at 7.19E-10 up 2.522143 STAT5B 
213006_at 6.03E-10 up 4.206962 CEBPD 
218221_at 1.49E-11 up 2.349603 ARNT 
218559_s_at 9.49E-07 up 3.354582 MAFB 
218880_at 5.34E-11 up 3.750719 FOSL2 
208808_s_at 1.07E-11 up 9.120556 HMGB 
200989_at 1.17E-06 up 2.997033 HIF1A 
 
 
 
 
 
 
Table 7. Cytokine 
   Probe ID Pvalue Arrow Fold Gene 
201108_s_at 2.84E-06 up 2.858913 THBS1 
201109_s_at 3.87E-05 up 3.674066 THBS1 
201110_s_at 2.02E-09 up 8.271206 THBS1 
203085_s_at 1.57E-08 up 2.327314 TGFB1 
203828_s_at 7.88E-05 down 2.130993 IL32 
205016_at 8.33E-10 up 4.855893 TGFA 
205992_s_at 4.40E-06 up 3.5756 IL15 
208114_s_at 7.75E-20 down 5.849659 ISG20L2 
208200_at 3.06E-11 down 4.80094 IL1A 
212195_at 3.90E-06 up 2.667476 IL6ST 
206488_s_at 1.04E-04 up 2.926877 CD36 
209555_s_at 2.87E-05 up 3.18128 CD36 
212657_s_at 2.96E-07 up 2.31195 IL1RN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Cytokine receptor 
  Probe ID Pvalue Arrow Fold Gene 
201642_at 1.42E-09 up 2.315 IFNGR2 
202727_s_at 1.44E-08 up 3.323753 IFNGR1 
202948_at 5.77E-10 up 6.463163 IL1R1 
203233_at 2.36E-10 up 3.270304 IL4R 
204191_at 2.98E-07 up 2.05704 IFNAR1 
204731_at 7.48E-21 down 11.93166 TGFBR3 
204786_s_at 5.23E-19 down 6.864011 IFNAR2 
205227_at 2.89E-05 up 2.68359 IL1RAP 
205291_at 2.89E-08 down 2.442178 IL2RB 
205403_at 1.87E-08 up 6.689801 IL1R2 
205707_at 1.73E-09 down 2.408515 IL17RA 
205798_at 2.48E-24 down 31.78504 IL7R 
205926_at 1.06E-09 down 2.187688 IL27RA 
205945_at 1.49E-22 down 16.68902 IL6R 
206618_at 4.70E-09 up 12.92154 IL18R1 
207072_at 5.22E-08 up 4.927116 IL18RAP 
211372_s_at 1.76E-08 up 10.6815 IL1R2 
211676_s_at 6.66E-09 up 4.607373 IFNGR1 
217489_s_at 2.79E-14 down 3.546462 IL6R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. CSF 
   Probe ID Pvalue Arrow Fold Gene 
205159_at 1.17E-06 up 2.511396 CSF2RB 
210340_s_at 4.36E-10 up 2.295372 CSF2RA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. TNF 
   Probe ID Pvalue Arrow Fold Gene 
202509_s_at 1.99E-12 down 2.4938 TNFAIP2 
206026_s_at 7.48E-06 up 3.620447 TNFAIP6 
206222_at 1.55E-06 down 2.076582 TNFRSF10C 
207536_s_at 5.06E-07 down 2.86682 TNFRSF9 
207643_s_at 3.72E-12 up 2.681254 TNFRSF1A 
207907_at 9.40E-17 down 3.895788 TNFSF14 
208296_x_at 2.21E-05 up 2.431529 TNFAIP8 
210260_s_at 4.11E-05 up 2.505209 TNFAIP8 
214329_x_at 1.19E-04 up 2.324046 TNFSF10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Chemokine 
   Probe ID Pvalue Arrow Fold Gene 
200660_at 9.23E-12 up 2.053883 S100A11 
202917_s_at 2.79E-12 up 2.617102 S100A8 
203535_at 3.98E-16 up 2.584441 S100A9 
204103_at 3.51E-09 down 2.364728 CCL4 
204351_at 7.20E-04 up 2.155134 S100P 
205099_s_at 6.98E-05 down 2.455516 CCR1 
205863_at 7.49E-14 up 4.166398 S100A12 
205898_at 6.76E-04 down 2.496165 CX3CR1 
206337_at 5.73E-08 down 5.099034 CCR7 
206366_x_at 1.36E-09 down 3.847104 XCL1 
206978_at 7.29E-05 up 2.362277 CCR2 
207165_at 6.52E-05 up 2.285972 HMMR 
208304_at 4.88E-05 down 3.621386 CCR3 
214370_at 5.04E-06 down 2.084171 S100A8 
214567_s_at 8.06E-08 down 2.902829 XCL1 /// XCL2 
221058_s_at 1.49E-09 up 2.15809 CKLF 
     
     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. PGD LTX 
   Probe ID Pvalue Arrow Fold Gene 
203913_s_at 1.26E-08 up 16.54476 HPGD 
203914_x_at 3.77E-08 up 14.66064 HPGD 
204445_s_at 2.84E-06 up 2.076126 ALOX5 
204446_s_at 1.01E-07 up 2.0434 ALOX5 
204748_at 0.019719 up 2.109052 PTGS2 
205128_x_at 5.85E-07 up 2.664767 PTGS1 
207206_s_at 1.59E-04 up 2.531166 ALOX12 
209533_s_at 3.14E-10 up 2.619734 PLAA 
210128_s_at 9.02E-10 up 2.505719 LTB4R 
210145_at 1.51E-12 up 3.476688 PLA2G4A 
211548_s_at 4.38E-08 up 12.3211 HPGD 
211549_s_at 3.53E-04 up 2.6726 HPGD 
211748_x_at 1.56E-06 down 2.033312 PTGDS 
214366_s_at 5.17E-10 up 3.681805 ALOX5 
215813_s_at 1.01E-08 up 3.363031 PTGS1 
215894_at 2.35E-14 down 10.40363 PTGDR 
216388_s_at 9.35E-07 up 2.104241 LTB4R 
208771_s_at 4.07E-08 up 2.455806 LTA4H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. Acute Response Protein 
 Probe ID Pvalue Arrow Fold Gene 
200602_at 3.75E-12 up 4.384286 APP 
206157_at 8.31E-08 up 3.272863 PTX3 
208248_x_at 2.42E-09 up 2.54326 APLP2 
208691_at 0.001264 up 2.485756 TFRC 
208702_x_at 7.55E-09 up 2.826174 APLP2 
208703_s_at 1.26E-07 up 3.047052 APLP2 
208704_x_at 1.61E-08 up 2.435629 APLP2 
211404_s_at 4.34E-10 up 2.927751 APLP2 
214875_x_at 1.32E-08 up 2.761566 APLP2 
214953_s_at 8.93E-05 up 2.120433 APP 
219890_at 1.43E-12 up 7.827181 CLEC5A 
220496_at 2.59E-07 up 3.327139 CLEC1B 
205033_s_at 1.17E-05 up 4.788064 DEFA1/A1B/A3 
207269_at 2.87E-05 up 6.665461 DEFA4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. Complement 
   Probe ID Pvalue Arrow Fold Gene 
200983_x_at 7.97E-09 up 3.370908 CD59 
200984_s_at 9.06E-10 up 3.891589 CD59 
200985_s_at 4.85E-11 up 6.593943 CD59 
201925_s_at 2.14E-07 up 5.613841 CD55 
201926_s_at 6.74E-09 up 3.830297 CD55 
202953_at 7.01E-06 up 2.526228 C1QB 
205786_s_at 5.02E-13 up 4.053864 ITGAM 
206244_at 6.06E-12 up 6.759067 CR1 
208783_s_at 0.004769 up 2.21095 CD46 
209906_at 7.48E-09 up 4.336492 C3AR1 
210184_at 1.17E-06 up 2.086657 ITGAX 
212463_at 2.34E-09 up 2.845059 CD59 
217552_x_at 5.04E-10 up 3.57143 CR1 
218232_at 1.52E-08 up 3.972673 C1QA 
218983_at 7.83E-08 up 2.636687 C1RL 
220088_at 9.13E-08 up 2.491036 C5AR1 
202910_s_at 3.42E-07 up 2.255245 CD97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15. NO/ NADPH oxidase 
  Probe ID Pvalue Arrow Fold Gene 
201940_at 9.58E-11 up 5.886338 CPD 
201941_at 1.14E-09 up 5.264568 CPD 
201942_s_at 6.35E-08 up 3.362135 CPD 
201943_s_at 7.91E-12 up 6.937615 CPD 
204961_s_at 7.26E-08 up 2.016737 NCF1/1B/1C 
207677_s_at 5.88E-10 up 2.661943 NCF4 
214084_x_at 1.31E-08 up 2.251172 NCF1C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16. MMP 
   Probe ID Pvalue Arrow Fold Gene 
203167_at 1.02E-13 up 3.135463 TIMP2 
203936_s_at 2.89E-16 up 10.59129 MMP9 
206871_at 1.04E-06 up 5.3948 ELANE 
207329_at 3.41E-11 up 32.06008 MMP8 
207890_s_at 1.30E-11 up 3.108211 MMP25 
202833_s_at 2.83E-09 up 2.778271 SERPINA1 
204614_at 5.64E-08 up 3.074429 SERPINB2 
212268_at 8.64E-11 up 5.643009 SERPINB1 
213572_s_at 7.52E-11 up 5.130388 SERPINB1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17. Caspase 
   Probe ID Pvalue Arrow Fold Gene 
202763_at 1.22E-06 up 2.523658 CASP3 
204780_s_at 1.71E-04 up 2.524168 FAS 
207500_at 4.39E-06 up 2.385929 CASP5 
208485_x_at 1.73E-08 down 2.568559 CFLAR 
209508_x_at 1.14E-10 down 2.749778 CFLAR 
210564_x_at 1.77E-07 down 2.357083 CFLAR 
210907_s_at 7.22E-06 up 2.816621 PDCD10 
211316_x_at 3.60E-13 down 3.914512 CFLAR 
211317_s_at 1.10E-07 down 2.657199 CFLAR 
211367_s_at 7.39E-06 up 2.2941 CASP1 
211862_x_at 3.34E-08 down 2.575973 CFLAR 
213596_at 4.92E-09 up 3.013394 CASP4 
214486_x_at 3.71E-08 down 2.177017 CFLAR 
215719_x_at 2.24E-06 up 3.678086 FAS 
221601_s_at 1.49E-09 down 4.178467 FAIM3 
221602_s_at 2.73E-12 down 3.899111 FAIM3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 18. Fc receptor 
   Probe ID Pvalue Arrow Fold Gene 
203561_at 6.67E-09 up 2.023942 FCGR2A 
204232_at 8.21E-11 up 2.713677 FCER1G 
207674_at 8.78E-08 up 6.420722 FCAR 
210992_x_at 1.24E-07 up 2.313229 FCGR2C 
211307_s_at 8.29E-08 up 4.563443 FCAR 
211395_x_at 1.20E-06 up 2.139768 FCGR2C 
211734_s_at 3.84E-05 down 3.85882 FCER1A 
211816_x_at 3.58E-05 up 2.405171 FCAR 
214511_x_at 2.07E-05 up 3.075548 FCGR1B 
216950_s_at 5.51E-08 up 5.08392 FCGR1A/1C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19. CD molecule 
   Probe ID Pvalue Arrow Fold Gene 
200663_at 7.97E-10 up 2.446524 CD63 
201005_at 4.83E-08 up 4.230153 CD9 
202351_at 5.59E-10 up 3.163429 ITGAV 
202638_s_at 7.74E-08 up 2.891012 ICAM1 
202878_s_at 8.07E-06 up 2.265542 CD93 
202910_s_at 3.42E-07 up 2.255245 CD97 
203645_s_at 2.02E-09 up 9.129274 CD163 
204306_s_at 2.48E-06 up 2.098005 CD151 
204489_s_at 2.80E-09 up 2.832196 CD44 
204490_s_at 3.30E-09 up 2.773283 CD44 
204661_at 2.08E-04 down 2.102266 CD52 
205173_x_at 8.14E-08 up 3.565981 CD58 
205789_at 6.34E-06 up 3.14233 CD1D 
205831_at 4.40E-10 down 3.924635 CD2 
205988_at 3.64E-19 down 5.606748 CD84 
206488_s_at 1.04E-04 up 2.926877 CD36 
206761_at 5.72E-06 down 2.026305 CD96 
208405_s_at 5.16E-06 up 2.167749 CD164 
208650_s_at 7.29E-08 up 4.591438 CD24 
208651_x_at 5.17E-10 up 3.761404 CD24 
208653_s_at 1.98E-11 up 4.511797 CD164 
208654_s_at 3.10E-07 up 5.153189 CD164 
209555_s_at 2.87E-05 up 3.18128 CD36 
209771_x_at 1.91E-08 up 4.956121 CD24 
209835_x_at 3.82E-07 up 2.377499 CD44 
210031_at 4.04E-09 down 3.14224 CD247 
211744_s_at 7.96E-09 up 3.998247 CD58 
211900_x_at 3.47E-14 down 2.437045 CD6 
211945_s_at 2.07E-06 up 2.577267 ITGB1 
212014_x_at 4.13E-07 up 2.48835 CD44 
212063_at 5.59E-07 up 2.205469 CD44 
213958_at 2.29E-08 down 2.119745 CD6 
215049_x_at 6.80E-09 up 8.964883 CD163 
216233_at 3.21E-06 up 4.34145 CD163 
216379_x_at 6.81E-09 up 5.765379 CD24 
216942_s_at 4.88E-06 up 3.031317 CD58 
217523_at 4.41E-13 down 6.665958 CD44 
219669_at 1.40E-13 up 34.68958 CD177 
222061_at 6.85E-09 up 3.64802 CD58 
222292_at 7.05E-11 down 2.150798 CD40 
266_s_at 1.78E-10 up 6.956197 CD24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20. Coagulation 
   Probe ID Pvalue Arrow Fold Gene 
203305_at 2.16E-04 up 2.180403 F13A1 
204714_s_at 1.87E-08 up 3.933558 F5 
205756_s_at 2.79E-05 up 2.08411 F8 
205871_at 7.54E-07 down 3.123419 PLGLA/B1/B2 
206655_s_at 2.25E-08 up 5.369561 GP1BB/SEPT5 
207808_s_at 6.30E-08 up 2.883896 PROS1 
210845_s_at 2.55E-07 up 2.502571 PLAUR 
211924_s_at 5.53E-07 up 2.325629 PLAUR 
212245_at 6.18E-07 up 2.301938 MCFD2 
213258_at 1.07E-06 up 2.352817 TFPI 
213506_at 0.002877 up 2.349815 F2RL1 
214415_at 1.30E-09 down 5.536361 PLGLB1/B2 
214866_at 5.37E-10 up 2.031086 PLAUR 
216956_s_at 4.64E-05 up 2.39087 ITGA2B 
218718_at 2.79E-10 up 9.385749 PDGFC 
204627_s_at 1.30E-06 up 4.180416 ITGB3 
203887_s_at 8.66E-09 up 4.530585 THBD 
203888_at 4.42E-08 up 2.810682 THBD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21. Glycolysis 
   Probe ID Pvalue Arrow Fold Gene 
200650_s_at 2.02E-09 up 2.710678 LDHA 
200737_at 2.94E-11 up 3.17309 PGK1 
201030_x_at 9.45E-05 down 2.016562 LDHB 
201251_at 2.51E-10 up 2.67251 PKM2 
202464_s_at 6.45E-09 up 7.300454 PFKFB3 
202934_at 9.80E-14 up 4.768903 HK2 
202990_at 2.15E-12 up 4.196534 PYGL 
203502_at 1.24E-04 up 3.670577 BPGM 
205936_s_at 5.17E-12 up 4.987516 HK3 
206348_s_at 9.53E-11 up 2.597892 PDK3 
208308_s_at 3.92E-09 up 2.215685 GPI 
209992_at 3.99E-09 up 11.77066 PFKFB2 
213453_x_at 2.13E-12 up 2.175151 GAPDH 
217294_s_at 3.28E-06 up 2.62132 ENO1 
217356_s_at 4.20E-08 up 2.028929 PGK1 
218273_s_at 1.01E-07 down 2.250674 PDP1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22. H-ATPase 
   Probe ID Pvalue Arrow Fold Gene 
200078_s_at 6.15E-13 up 2.530917 ATP6V0B 
201171_at 4.49E-10 up 2.484021 ATP6V0E1 
201443_s_at 5.84E-06 up 2.32877 ATP6AP2 
201971_s_at 4.45E-13 down 5.207561 ATP6V1A 
202872_at 1.95E-10 up 6.183733 ATP6V1C1 
202874_s_at 6.99E-10 up 5.718367 ATP6V1C1 
204158_s_at 5.14E-08 up 2.068726 TCIRG1 
208898_at 2.66E-09 up 2.413653 ATP6V1D 
213587_s_at 1.13E-08 down 2.067119 ATP6V0E2 
206208_at 1.00E-11 up 3.51149 CA4 
206209_s_at 4.18E-15 up 7.982899 CA4 
209301_at 2.78E-06 up 3.422036 CA2 
212536_at 4.38E-09 up 4.21056 ATP11B 
213582_at 1.89E-08 up 2.241957 ATP11A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 23. Vasodilator 
   Probe ID Pvalue Arrow Fold Gene 
201494_at 1.01E-08 up 2.190291 PRCP 
202912_at 1.20E-08 up 4.330455 ADM 
212741_at 0.004196 up 2.027247 MAOA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 24. NK cell 
   Probe ID Pvalue Arrow Fold Gene 
202379_s_at 2.01E-30 down 26.43984 NKTR 
205821_at 1.39E-12 down 3.985353 KLRK1 
207509_s_at 7.71E-10 down 2.948439 LAIR2 
207795_s_at 1.01E-09 down 3.216148 KLRD1 
210288_at 1.62E-11 down 5.382525 KLRG1 
210606_x_at 1.91E-09 down 3.341239 KLRD1 
214470_at 1.11E-04 down 2.103258 KLRB1 
215338_s_at 1.06E-24 down 14.54682 NKTR 
220646_s_at 1.34E-04 down 2.386466 KLRF1 
205488_at 1.01E-05 down 2.867692 GZMA 
206666_at 1.84E-07 down 3.446082 GZMK 
207460_at 3.78E-09 down 2.502287 GZMM 
210164_at 8.91E-09 down 3.75597 GZMB 
210321_at 8.94E-10 down 5.800327 GZMH 
214617_at 2.22E-06 down 2.646147 PRF1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 25. T cell 
   Probe ID Pvalue Arrow Fold Gene 
205039_s_at 2.79E-08 down 2.22558 IKZF1 
205255_x_at 3.09E-08 down 2.955244 TCF7 
205456_at 5.31E-08 down 2.877146 CD3E 
205488_at 1.01E-05 down 2.867692 GZMA 
205495_s_at 5.33E-10 down 4.378694 GNLY 
205758_at 1.20E-07 down 3.258815 CD8A 
206666_at 1.84E-07 down 3.446082 GZMK 
206804_at 1.10E-15 down 5.118528 CD3G 
207460_at 3.78E-09 down 2.502287 GZMM 
208003_s_at 5.52E-18 down 12.03963 NFAT5 
209670_at 5.21E-06 down 2.475029 TRAC 
209671_x_at 3.58E-08 down 2.774547 TRAC 
209813_x_at 1.49E-09 down 4.424708 TARP 
210164_at 8.91E-09 down 3.75597 GZMB 
210321_at 8.94E-10 down 5.800327 GZMH 
210370_s_at 1.34E-07 down 2.482685 LY9 
210555_s_at 1.02E-07 down 2.476832 NFATC3 
210556_at 4.68E-08 down 2.850907 NFATC3 
210915_x_at 6.23E-06 down 2.847533 TRBC1 
210972_x_at 1.78E-07 down 2.875805 TRAC/J17/V20 
211144_x_at 5.76E-08 down 3.696107 TARP/TRGC2 
211796_s_at 6.35E-06 down 2.926207 TRBC1/C2 
211902_x_at 8.99E-07 down 2.286838 TRD@ 
212759_s_at 3.98E-16 down 3.926594 TCF7L2 
212762_s_at 2.70E-09 down 2.376013 TCF7L2 
212808_at 1.21E-21 down 5.549449 NFATC2IP 
213193_x_at 2.53E-06 down 2.918569 TRBC1 
213539_at 1.00E-08 down 3.193378 CD3D 
213830_at 5.93E-08 down 3.51036 TRD@ 
214617_at 2.22E-06 down 2.646147 PRF1 
215092_s_at 1.36E-09 down 2.475134 NFAT5 
215806_x_at 1.02E-08 down 4.078028 TARP/TRGC2 
216191_s_at 4.71E-07 down 4.762182 TRDV3 
216920_s_at 2.28E-10 down 5.341667 TARP/TRGC2 
217143_s_at 1.26E-08 down 6.055404 TRD@ 
217526_at 1.43E-12 down 3.846013 NFATC2IP 
217527_s_at 2.12E-13 down 5.801224 NFATC2IP 
220684_at 7.39E-09 down 2.077709 TBX21 
220704_at 2.15E-10 down 5.686157 IKZF1 
37145_at 9.67E-10 down 4.340701 GNLY 
214032_at 6.60E-08 down 2.523588 ZAP70 
204890_s_at 1.65E-07 down 2.638662 LCK 
204891_s_at 4.58E-08 down 3.313788 LCK 
205831_at 4.40E-10 down 3.924635 CD2 
201565_s_at 8.13E-13 down 4.167651 ID2 
213931_at 7.33E-08 down 3.546731 ID2/2B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 26. B cell 
   Probe ID Pvalue Arrow Fold Gene 
221969_at 9.96E-13 down 4.199424 PAX5 
203140_at 3.09E-10 up 3.687249 BCL6 
210105_s_at 9.37E-10 down 3.319013 FYN 
210754_s_at 2.98E-10 down 3.545109 LYN 
205039_s_at 2.79E-08 down 2.22558 IKZF1 
211430_s_at 0.015735 up 2.830679 IGHG1/G2 
211643_x_at 0.024398 up 2.10616 IGK 
212592_at 0.017267 up 2.569312 IGJ 
212827_at 0.008027 down 2.240154 IGHM 
214677_x_at 0.031357 up 2.035694 IGLV1-44  
214768_x_at 0.006798 up 2.374888 IGKV1-5 
217022_s_at 5.28E-05 up 5.197489 IGHA1 /A2 
210970_s_at 2.98E-06 up 2.298244 IBTK 
217620_s_at 4.31E-12 down 2.785986 PIK3CB 
221756_at 5.52E-10 down 2.616271 PIK3IP1 
204053_x_at 1.57E-06 up 2.560581 PTEN 
204054_at 2.56E-10 up 5.50691 PTEN 
211711_s_at 2.54E-08 up 4.673204 PTEN 
206370_at 2.95E-09 down 2.443374 PIK3CG 
212240_s_at 4.29E-13 down 4.50699 PIK3R1 
212249_at 1.96E-06 down 2.560644 PIK3R1 
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